Viking Disappoints – Novo Nordisk Remains No. 1 in Oral Weight Loss Medications
20 million potential MASH patients in the U.S. alone!
15% weight loss with oral Semaglutide tablet – unmatched!
Reading Time: 1 minute
The disappointing study data from Viking has confirmed it again: Novo Nordisk's oral Semaglutide tablet sets the benchmark with about 15% weight loss. At the same time, the FDA approval for MASH – a disease affecting more than 20 million people in the U.S. alone – opens up a gigantic new market. It is clear: Novo is not only maintaining its leading position but also expanding it. After the overall share price decline over the past 12 months, I see the stock as one of the most promising growth stocks in the healthcare sector in the long term....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
